Study to characterize the effect of elexacaftor/tezacaftor/ivacaftor on forced exhalation in 1 second percent predicted and side effect profile in people with cystic fibrosis and a baseline FEV1 of less than 40 percent predicted
Latest Information Update: 01 Jul 2021
Price :
$35 *
At a glance
- Drugs Elexacaftor/ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- 01 Jul 2021 New trial record
- 19 May 2021 Results presented at the 117th International Conference of the American Thoracic Society.